Research of exspresion of the enzyme Topoisomerase-II Alfa in different molecular-genetic subtypes of breast cancer
DOI: 10.22138/2500-0918-2016-14-4-30-37
E.A. Novikova, A.N. Kodintsev, S.V. Sazonov, E.V. Arutyunyan,
N.V. Kazantseva, A.A. Brilliant, S.L. Leontiev
Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
Ural State Medical University, Yekaterinburg, Russian Federation
Abstract.
Molecular-genetic classification of breast cancer developed on the basis of immunohistochemical study of four markers, (ER receptors, PR, Her2+ /neu, Ki-67), which is used to decide on the advisability of the appointment of hormonal and chemotherapy. With the help of computer programs was conducted IHC analysis study of 691 blocks invasive carcinomas: 5 cluster groups were obtained, each of which had its own individual profile IHC. The analysis showed that the predominant subtype of breast cancer is the Luminal A (28.4%), the Luminal B (HER2-) negative (26.9%) and HER2 — positive (8.8%). Number of cases of Luminal B subtype of breast cancer (26.9%). Overexpression of Tor2a not found only in the Luminal A subtype. The triple negative and HER2+ subtypes experienced the highest levels of expression Top2a (27.8% and 21.3%, respectively). As in all subtypes statistically significant correlation between the expression of Top2a and Ki-67. The weak correlation between the expression of Top2a with HER2 is found in HER2- positive and HER2- negative tumors (in the triple negative subtype (r = 0,71) and Luminal B (HER2+) (r = 0,69).
Keywords:
breast cancer, ICH, exspression, topoisomerase-IIa
REFERENCES
1. Cheang M.C.U., Chia S.K., Voduc D ., Gao D., Leung S., Snider J. et al. Ki 67 index, HER-2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 2009. Vol. 101. pp. 736–750. DOI:10.1093/jnci/djp082.
2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumors Nature. 2000. Vol. 406. pp. 747–752. DOI:10.1038/35021093.
3. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immnohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLos. Med. 2010. Vol. 7. pp. 279. DOI: 10.1371/journal.pmed.1000279.
4. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst. 2003. Vol. 95. pp. 142-153. DOI: 10.1186/bcr3035.
5. Runnak M.A., Hazha M.A., Hemin H.A., et al. A population-based study of Kurdish breast cancer in northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. BMC Women's Health 2012, 12:16.
6. Gluz O., Lliedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple- negative breast cancer- current status and future directions. Ann. Oncol. 2009, No. 20, pp. 1913-1927. DOI:10.1093/annonc/mdp492.
7. Shimizu C., Ando M., Kouno T., Katsumata N., Fujiwara Y. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn. J. Clin. Oncol. 2007, No. 37, pp. 1-8, DOI:10.1093/jjco/hyl122.
8. Dent R., Trudeau M., Pritchard K.I., et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, Vol. 13. pp. 4429-4434. DOI:10.1007/s10549-014-2978-7.
9. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple- negative breast cancer. J. Clin. Oncol. 2008. Vol. 26. pp. 1275-1281. DOI: 10.1200/JCO.2007.14.4147.
10. Sazonov S.V., Konishev K.V., Kazantseva N.V., Tokareva M.V., Brilliant J.M. Histological and immunohistochemical manifestations epithelium-mesenchymal transition in triple negative breast cancer [Gistologicheskie i immunogistohimicheskie proiavlenia epitelio-mezenhimalnogo perihoda v troinom negativnom rake grudnoi gelezi]. Herald of Ural Medical Academic Science [Vestnik ural'skoi meditsinskoi akademicheskoi nauki]. 2016, No. 2, pp. 53-63, DOI: 10.22138/2500-0918-2016-15-3-85-96, [In Russ.].
11. Yastrebov A.P., Grebnev D.Y., Maklakova I.Y. The stem cells, their properties, and the sources of the role in regenerative medicine [Stvolovie kletki, ih raznovidnosti i roli v regenerativnoi meditcine]. Ekaterinburg, 2016, (In Russ.).
12. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005. Vol. 23. pp. 7212-7220. DOI:10.1200/JCO.2005.07.501
13. Brilliant A.A., Sazonov S.V. Changing the receptor status Group proliferative activity of breast carcinomas [Izmenenie statusa receptorov b proliferativnoi aktivnosti karcinome grudi]. Herald of Ural Medical Academic Science [Vestnik ural'skoi meditsinskoi akademicheskoi nauki]. 2013, No. 1 (43), pp. 61-63, [In Russ.].
14. Sazonov .S.V, Brilliant A.A., Dorofeev A.V., Demidov S.M. Some expression patterns Estrogen, Progesterone Receptor and Ki-67 on tumor cells of breast carcinoma [Expressia estrogene, progesteron receptor i Ki-67 opuholevih kletkah karcinomi grudi]. Urals Medical Journal [Uralski Medicinski Jurnal]. 2010, No. 77 (12), pp. 68-72, [In Russ.].
15. Jones R.L., Salter J.A., Herm R., et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res.Treat. 2010. Vol.119. pp. 315-323. DOI: 10.1007/s12282-013-0482-2.
16. Keam B., Im S.A., Kim H.J., et al. Prognostic impact of cliniclpathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple-negative breast cancer. BMC Cancer 2007, 7:203. DOI: 10.1186/1471-2407-7-203.
17. Keam B., Im S.A., Kim H.J., et al. Ki-67 can be used for further classification of triple- negative breast cancer in two subtypes with different response and prognosis. Br. Cancer Res. 2011, No. 13, p. 22, DOI:10.1186/bcr2834.
18. Petit T., Wilt M., Velten M., et al. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur. J. Cancer 2004, Vol. 40 (2), pp. 205–11.
19. Romero A., Martin M., Maggie C.U. Cheang at.ol. Assassment of Topoisomerase II alpha Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization. The American Journal of Pathology. 2011. Vol. 4. pp. 1453-71. DOI:10.1136/jclinpath-2011-200342
20. Linch B.J., Guinee D.G., Holden J.A. Human DNA topoisomerase II alpha: a new markers of cell proliferation in invasive breast cancer. Human Pathol. 1997. Vol. 28. pp. 1180-88. DOI: 10.1309/AJCPROG61USKCBEI.
21. Hala S., Redey E.I., Aiad H.A., et al. Immunochistochemical expression of topoisomerase II a and tissue ingibitor of mrtalloproteinases 1 in locally advanced breast carcinoma. Menoufia Medical Journal. 2014. Vol. 27. pp. 1-9. DOI: 10.11648/j.ijmi.20150302.14.
22. Kodintsev A.N., Novikova E.A., Sazonov S.V., Krokhalev V.Y. The study overexpression of the enzyme topoisomerase II-Group and breast carcinoma cells with different protein expression status of HER-2. [Isuchenie expressii fermenta topoisomerasi 2 v karcinomi grudi s razlichnih expressiei belkov]. Herald of Ural Medical Academic Science [Vestnik ural'skoi meditsinskoi akademicheskoi nauki]. 2014, No. 5. pp.79-83. [In Russ.].
23. Arutyunyan E.V., Brilliant A.A., Novikova E.A., Sazonov S.V. Some expression patterns immunohistochemical markers on cells of breast carcinoma [Expressia immunogistohimicheskih markerov na kletkah karcinomi grudi]. Ural Medical Journal [Uralski Medicinski Jurnal]. 2014, No. 2 (116), pp. 5-8. [In Russ.].
Authors
Novikova Evgenia A.
Ural State Medical University of Ministry of Health of the Russian Federation
Assistant Professor of Histology, Cytology and Embryology
Russian Federation, 620028, Yekaterinburg, Repin str. 3
Kodintsev Anton N.
Ural State Medical University of Ministry of Health of the Russian Federation
5th year student
Russian Federation, 620028, Yekaterinburg, Repin str. 3
Sazonov Sergey V.
Ural State Medical University
MD, Professor, The Head of the Department of histology, cytology and embryology
620137, Yekaterinburg, Russian Federation, Vilonova st., 76a
prof-ssazonov@yandex.ru
Arutyunyan Ekaterina V.
Institute of Medical Cell Technologies
Researcher postmortem department of Pathomorphology
620137, Yekaterinburg, Russian Federation, Vilonova st., 76a
imct@celltechnologies.ru
Kazantseva Natalia V.
The Clinical Cancer Center of the Sverdlovsk region
The graduate student of Professor, The Head of the department of pathomorphology and the
Institute of Medical Cell Technologies
Department of Pathomorphology
620137, Vilonova str., 76a, Yekaterinburg, Russian Federation
imct@celltechnologies.ru
Brilliant Alexander A.
Institute of Medical Cell Technologies
Leading researcher at the post-mortem separation, Ph.D.
620137, Vilonova str., 76a, Yekaterinburg, Russian Federation
imct@celltechnologies.ru
Leontiev Sergey L.
Institute of Medical Cell Technologies
Head of GAUZ SO Institute of Medical Cell Technologies, MD, Professor
620137, Vilonova str., 76a, Yekaterinburg, Russian Federation
Received 29.10.2016
For citation:
Novikova E.A., Kodintsev A.N., Sazonov S.V., Arutyunyan E.V., Kazantseva N.V., Brilliant A.A., Leontiev S.L. Jespressija fermenta topoizomeraza-II al'fa v molekuljarno-geneticheskih podtipah raka molochnoj zhelezy [Research of exspresion of the enzyme topoisomerase-II Alfa in different molecular-genetic subtypes of breast cancer] Vestn. Ural. Med. Akad. Nauki. – Journal of Ural Medical Academic Science. 2016, no. 4, pp. 30–37. DOI: 10.22138/2500-0918-2016-14-4-33-37 [In Russ.]
